{"id":7264,"date":"2020-12-23T20:21:46","date_gmt":"2020-12-23T20:21:46","guid":{"rendered":"https:\/\/by-tv.co.uk\/?p=7264"},"modified":"2020-12-23T20:21:46","modified_gmt":"2020-12-23T20:21:46","slug":"kovid-19-asilari-arasinda-3-farkli-yontemle-uretilen-6-aday-one-cikiyor","status":"publish","type":"post","link":"https:\/\/by-tv.co.uk\/en\/kovid-19-asilari-arasinda-3-farkli-yontemle-uretilen-6-aday-one-cikiyor\/","title":{"rendered":"Kovid-19 a\u015f\u0131lar\u0131 aras\u0131nda 3 farkl\u0131 y\u00f6ntemle \u00fcretilen 6 aday \u00f6ne \u00e7\u0131k\u0131yor"},"content":{"rendered":"

ANKARA (AA) – Kovid-19 a\u015f\u0131 adaylar\u0131ndan ikisi yayg\u0131n kullan\u0131m ve acil kullan\u0131m onaylar\u0131 al\u0131rken, Rusya’da ve \u00c7in’de geli\u015ftirilen baz\u0131 a\u015f\u0131 adaylar\u0131 s\u0131n\u0131rl\u0131 olarak kullan\u0131lmaya ba\u015fland\u0131. \u0130ngiltere’de ve ABD’de risk grubundaki ki\u015filere ilk a\u015f\u0131lar vuruldu. \u00c7ok say\u0131da \u00fclke a\u015f\u0131 tedariki i\u00e7in milyonlarca dozluk \u00f6n sat\u0131n al\u0131m s\u00f6zle\u015fmeleri imzalad\u0131.<\/p>\n

D\u00fcnyada en fazla umut ba\u011flanan potansiyel a\u015f\u0131lar aras\u0131nda \u00fc\u00e7 farkl\u0131 y\u00f6ntemle geli\u015ftirilen alt\u0131 aday \u00f6ne \u00e7\u0131k\u0131yor. Bunlar aras\u0131nda ABD ve \u0130ngiltere’de yayg\u0131n ve acil kullan\u0131m\u0131na onay verilen RNA temelli iki a\u015f\u0131, \u0130ngiltere ve Rusya’da geli\u015ftirilen vir\u00fcs vekt\u00f6r\u00fc i\u00e7eren iki a\u015f\u0131 ile \u00c7in’de geli\u015ftirilen iki inaktif a\u015f\u0131 bulunuyor.<\/p>\n

A\u015f\u0131 t\u00fcrleri<\/h4>\n

A\u015f\u0131 \u00fcreticileri Kovid-19 a\u015f\u0131s\u0131n\u0131 geli\u015ftirmek i\u00e7in \u00fc\u00e7 yayg\u0131n y\u00f6nteme ba\u015fvuruyor. Bu y\u00f6ntemlerden en s\u0131k kullan\u0131lan ilkinde, a\u015f\u0131 form\u00fcl\u00fcne vir\u00fcs\u00fcn zay\u0131flat\u0131lm\u0131\u015f, etkisi azalt\u0131lm\u0131\u015f bir versiyonu konuluyor. Vir\u00fcs\u00fcn zay\u0131f haliyle kar\u015f\u0131la\u015fan v\u00fccudun ba\u011f\u0131\u015f\u0131kl\u0131k sa\u011flayacak savunmalar\u0131 geli\u015ftirmesini ama\u00e7layan bu t\u00fcrden a\u015f\u0131lara “inaktif a\u015f\u0131” ad\u0131 veriliyor.<\/p>

\"\"<\/a><\/div>\n

A\u015f\u0131 \u00e7al\u0131\u015fmalar\u0131nda klinik denemelerde y\u00fcksek etkinlik sa\u011flayan ikinci y\u00f6ntemde ise DNA ve RNA gibi genetik yap\u0131 ta\u015flar\u0131 i\u00e7eren a\u015f\u0131 form\u00fclleri geli\u015ftiriliyor. Bu a\u015f\u0131lar vir\u00fcsten al\u0131nm\u0131\u015f genetik bile\u015fenlerle ba\u011f\u0131\u015f\u0131kl\u0131\u011fa yard\u0131mc\u0131 baz\u0131 enzimleri harekete ge\u00e7irmeyi ve h\u00fccre d\u00fczeyinde ba\u011f\u0131\u015f\u0131kl\u0131k tepkilerini uyand\u0131rmay\u0131 ama\u00e7l\u0131yor.<\/p>\n

A\u015f\u0131 geli\u015ftirilmek i\u00e7in yayg\u0131n olarak kullan\u0131lan \u00fc\u00e7\u00fcnc\u00fc y\u00f6ntemde ise ba\u015fka vir\u00fcs t\u00fcrlerinden hedef vir\u00fcse genetik bile\u015fenler ekleniyor. “Vir\u00fcs vekt\u00f6r\u00fc” ad\u0131 verilen bu y\u00f6ntem i\u00e7in Kovid-19 a\u015f\u0131 \u00e7al\u0131\u015fmalar\u0131nda en s\u0131k kullan\u0131lan vir\u00fcs t\u00fcr\u00fc so\u011fuk alg\u0131nl\u0131\u011f\u0131na yol a\u00e7an adenovir\u00fcsler. Vir\u00fcs vekt\u00f6rleri, ba\u015fka bir vir\u00fcs\u00fcn zay\u0131flat\u0131lm\u0131\u015f ve kendini \u00e7o\u011faltamayan versiyonuna aktar\u0131lan vir\u00fcs bile\u015fenleri arac\u0131l\u0131\u011f\u0131yla v\u00fccutta ba\u011f\u0131\u015f\u0131kl\u0131k tepkisi yaratmay\u0131 hedefliyor.<\/p>\n

Bu y\u00f6ntemler d\u0131\u015f\u0131nda protein bile\u015fenleri, vir\u00fcs benzeri molek\u00fcller, antijen-sunucu h\u00fccreler vb. kullan\u0131larak da a\u015f\u0131 form\u00fclleri geli\u015ftirilebiliyor.<\/p>\n

RNA a\u015f\u0131lar\u0131: BioNTech\/Pfizer ve Moderna<\/h4>\n

Amerikan ila\u00e7 \u015firketi Pfizer ile T\u00fcrk bilim insan\u0131 Prof. Dr. U\u011fur \u015eahin’in kurucu orta\u011f\u0131 oldu\u011fu Alman biyoteknoloji firmas\u0131 BioNTech’in geli\u015ftirdi\u011fi Kovid-19 a\u015f\u0131s\u0131 ile Amerikan biyoteknoloji \u015firketi Moderna’n\u0131n ABD Ulusal Alerji ve Bula\u015f\u0131c\u0131 Hastal\u0131klar Enstit\u00fcs\u00fc (NIAID) deste\u011finde geli\u015ftirdi\u011fi a\u015f\u0131, \u00fc\u00e7\u00fcnc\u00fc a\u015fama denemelerde y\u00fcksek etkinlik g\u00f6sterdi\u011fi bildirilen ilk a\u015f\u0131lar oldu.<\/p>\n

Her iki a\u015f\u0131 da form\u00fcl\u00fcnde mesajc\u0131 ribon\u00fckleik asit (mRNA) i\u00e7eriyor. BioNTech\/Pfizer’in geli\u015ftirdi\u011fi “BNT162b2” adl\u0131 a\u015f\u0131, form\u00fcl\u00fcndeki RNA bile\u015fimi sayesinde Kovid-19’u etkisiz k\u0131lan kan \u015fekeri enzimleri ile al\u0131mlay\u0131c\u0131-ba\u011flay\u0131c\u0131 imm\u00fcnoglobulin G antikorlar\u0131n\u0131 harekete ge\u00e7irmeyi, h\u00fccre d\u00fczeyinde ba\u011f\u0131\u015f\u0131kl\u0131k tepkisi yaratan CD4+ ve CD8+ glikoproteinlerini art\u0131rmay\u0131 ama\u00e7l\u0131yor.<\/p>\n

Moderna’n\u0131n “mRNA-1273” ad\u0131n\u0131 verdi\u011fi a\u015f\u0131 aday\u0131 ise vir\u00fcs\u00fcn insan h\u00fccresine tutunmas\u0131n\u0131 sa\u011flayan “\u00e7ivi proteini” ad\u0131 verilen enzimi bask\u0131layarak v\u00fccutta ba\u011f\u0131\u015f\u0131kl\u0131k sa\u011flamay\u0131 hedefliyor. A\u015f\u0131n\u0131n form\u00fcl\u00fcndeki mesajc\u0131 RNA ile Kovid-19’un \u00e7ivi proteinini yapay olarak \u00fcreterek v\u00fccudun h\u00fccre d\u00fczeyindeki savunmas\u0131n\u0131 harekete ge\u00e7irmeyi hedefliyor.<\/p>\n

BioNTech\/Pfizer a\u015f\u0131s\u0131, \u0130ngiltere \u0130la\u00e7 ve Sa\u011fl\u0131k \u00dcr\u00fcnleri D\u00fczenleme Kurumunun (MHRA) 2 Aral\u0131k’ta yayg\u0131n kullan\u0131m\u0131na onay vermesiyle “d\u00fcnyada tescillenen ilk Kovid-19 a\u015f\u0131s\u0131” oldu. ABD G\u0131da ve \u0130la\u00e7 \u0130daresi (FDA) 11 Aral\u0131k’ta a\u015f\u0131n\u0131n acil kullan\u0131m\u0131na onay verirken, Avrupa \u0130la\u00e7 Ajans\u0131 (EMA) Avrupa Birli\u011fi (AB) \u00fclkelerinde kullan\u0131m\u0131n\u0131 onaylad\u0131.<\/p>\n

\u0130ngiltere’de 91 ya\u015f\u0131ndaki Kuzey \u0130rlandal\u0131 Margaret Keenan, ABD’de ise New York’ta \u00e7al\u0131\u015fan 52 ya\u015f\u0131ndaki Afro-Amerikal\u0131 hem\u015fire Sandra Lindsey, BioNTech\/Pfizer a\u015f\u0131s\u0131n\u0131 ilk yapt\u0131ranlar oldu. A\u015f\u0131n\u0131n Almanya’da 27 Aral\u0131k’ta uygulanmaya ba\u015flanmas\u0131 planlan\u0131yor.<\/p>\n

Moderna’n\u0131n a\u015f\u0131s\u0131 ise 19 Aral\u0131k’ta FDA’dan acil kullan\u0131m onay\u0131 ald\u0131. A\u015f\u0131, ilk kez 21 Aral\u0131k’ta Connecticut eyaletinde Afro-Amerikal\u0131 hem\u015fire Mandy Delgado’ya uyguland\u0131. ABD Sa\u011fl\u0131k Bakan\u0131 Alex Azar ile Ulusal Alerji ve Bula\u015f\u0131c\u0131 Hastal\u0131klar Enstit\u00fcs\u00fc Direkt\u00f6r\u00fc Dr. Anthony Fauci, 22 Aral\u0131k’ta a\u015f\u0131y\u0131 yapt\u0131rarak yurtta\u015flara g\u00fcvenli oldu\u011fu mesaj\u0131n\u0131 verdi.<\/p>\n

Her iki RNA a\u015f\u0131s\u0131 da klinik denemelerde y\u00fcksek etkinlik g\u00f6sterdi fakat a\u015f\u0131lar\u0131n bile\u015fimlerinin bozulmamas\u0131 i\u00e7in \u00e7ok d\u00fc\u015f\u00fck s\u0131cakl\u0131klarda muhafaza edilmesi gerekiyor. BioNTech\/Pfizer a\u015f\u0131s\u0131 i\u00e7in bu s\u0131cakl\u0131k s\u0131f\u0131r\u0131n alt\u0131nda 70 derece iken, Moderna a\u015f\u0131s\u0131 i\u00e7in s\u0131f\u0131r\u0131n alt\u0131nda 20 derece. Bu durum a\u015f\u0131lar\u0131n saklama ve da\u011f\u0131t\u0131m maliyetini art\u0131r\u0131yor.<\/p>\n

Vir\u00fcs vekt\u00f6rleri: Oxford\/AstraZeneca ve Rus a\u015f\u0131lar\u0131<\/h4>\n

\u0130ngiltere’de Oxford \u00dcniversitesi Jenner Enstit\u00fcs\u00fc ile Oxford A\u015f\u0131 Grubu i\u015f birli\u011finde geli\u015ftirilen ve \u00fcretim lisans\u0131 \u0130ngiliz-\u0130sve\u00e7 ila\u00e7 \u015firketi AstraZeneca taraf\u0131ndan sat\u0131n al\u0131nan a\u015f\u0131 aday\u0131 ile Rusya’da Gamaleya Ulusal Epidemiyoloji ve Mikrobiyoloji Enstit\u00fcs\u00fc taraf\u0131ndan geli\u015ftirilen a\u015f\u0131 aday\u0131, vir\u00fcs vekt\u00f6r\u00fc y\u00f6ntemiyle geli\u015ftirilen a\u015f\u0131lar aras\u0131nda en fazla umut ba\u011flanan \u00e7al\u0131\u015fmalar olarak g\u00f6r\u00fcl\u00fcyor.<\/p>\n

Oxford’un “AZD1222” adl\u0131 a\u015f\u0131 aday\u0131, so\u011fuk alg\u0131nl\u0131\u011f\u0131na yol a\u00e7an bir adenovir\u00fcs\u00fcn zay\u0131flat\u0131lm\u0131\u015f ve kendini \u00e7o\u011faltamayan versiyonunu i\u00e7eriyor. Bile\u015fimine Kovid-19’un insan h\u00fccrelerine tutunmas\u0131n\u0131 sa\u011flayan \u00e7ivi proteini eklenen adenovir\u00fcs, enzimin yapay olarak ortaya \u00e7\u0131kmas\u0131n\u0131 ve v\u00fccudun buna kar\u015f\u0131 koruyucu antikorlar \u00fcreterek ger\u00e7ek vir\u00fcse kar\u015f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k kazanmas\u0131n\u0131 ama\u00e7l\u0131yor.<\/p>\n

Rusya’n\u0131n “Sputnik V” ad\u0131n\u0131 verdi\u011fi a\u015f\u0131 aday\u0131 da Oxford a\u015f\u0131s\u0131 gibi, so\u011fuk alg\u0131nl\u0131\u011f\u0131na yol a\u00e7an bir adenovir\u00fcsten al\u0131nan, ayr\u0131 dozlar halinde uygulanan iki vir\u00fcs bile\u015feni (rAd26 ve rAd5) i\u00e7eriyor.<\/p>\n

Oxford \u00dcniversitesi, 23 Kas\u0131m’da yapt\u0131\u011f\u0131 a\u00e7\u0131klamada, halen devam eden \u00fc\u00e7\u00fcnc\u00fc a\u015fama denemelerin ilk sonu\u00e7lar\u0131na g\u00f6re, potansiyel Kovid-19 a\u015f\u0131s\u0131n\u0131n tek doz uygulanmas\u0131 halinde y\u00fczde 70, \u00f6nce yar\u0131m doz, ard\u0131ndan tam doz uygulanmas\u0131 halinde ise y\u00fczde 90 etkili oldu\u011fu bildirdi.<\/p>\n

Gamaleya Enstit\u00fcs\u00fc ise 14 Aral\u0131k’ta yapt\u0131\u011f\u0131 a\u00e7\u0131klamada, halen devam eden \u00fc\u00e7\u00fcnc\u00fc a\u015fama denemelerde a\u015f\u0131n\u0131n etkililik d\u00fczeyinin y\u00fczde 91,4 oldu\u011funu belirtti.<\/p>\n

Oxford \u00dcniversitesi ve Gamaleya Enstit\u00fcs\u00fc, 11 Aral\u0131k’ta yapt\u0131klar\u0131 ortak a\u00e7\u0131klamada, ayn\u0131 y\u00f6ntemle geli\u015ftirilen iki a\u015f\u0131 aday\u0131n\u0131n birlikte uyguland\u0131\u011f\u0131nda daha etkili olup olmayaca\u011f\u0131n\u0131 ara\u015ft\u0131rmak \u00fczere klinik denemeler y\u00fcr\u00fcteceklerini duyurdu.<\/p>\n

\u00c7in’in inaktif a\u015f\u0131lar\u0131: Sinopharm ve Sinovac<\/h4>\n

\u00d6te yandan “inaktif a\u015f\u0131” y\u00f6ntemi, viral hastal\u0131klar\u0131n genelinde oldu\u011fu gibi Kovid-19 a\u015f\u0131s\u0131 i\u00e7in y\u00fcr\u00fct\u00fclen a\u015f\u0131 \u00e7al\u0131\u015fmalar\u0131nda en yayg\u0131n kullan\u0131lan y\u00f6ntemlerden biri olarak \u00f6ne \u00e7\u0131k\u0131yor. Bu t\u00fcr a\u015f\u0131larda vir\u00fcs\u00fcn zay\u0131flat\u0131larak etkisi azalt\u0131lm\u0131\u015f bir versiyonu a\u015f\u0131 form\u00fcl\u00fcne konuluyor. \u00c7in’de kamuya ait ila\u00e7 firmalar\u0131 Sinopharm ve Sinovac taraf\u0131ndan geli\u015ftirilen a\u015f\u0131 adaylar\u0131 en fazla umut ba\u011flanan inaktif a\u015f\u0131 \u00e7al\u0131\u015fmalar\u0131 olarak g\u00f6r\u00fcl\u00fcyor.<\/p>\n

Sinopharm’\u0131n Vuhan Viroloji Enstit\u00fcs\u00fc ve Pekin Biyolojik \u00dcr\u00fcnler Enstit\u00fcs\u00fc ile geli\u015ftirdi\u011fi a\u015f\u0131 aday\u0131, form\u00fcl\u00fcnde Kovid-19’un “etkisizle\u015ftirilmi\u015f” bir hali olan vir\u00fcs bile\u015feni bulunduruyor. “BBIBP-CorV” ad\u0131 verilen a\u015f\u0131 aday\u0131, v\u00fccudun g\u00fc\u00e7s\u00fczle\u015ftirilmi\u015f vir\u00fcse kar\u015f\u0131 do\u011fal korumalar\u0131n\u0131 canland\u0131rmay\u0131, bu yolla ba\u011f\u0131\u015f\u0131kl\u0131k tepkisi yaratmay\u0131 ama\u00e7l\u0131yor.<\/p>\n

Pekin y\u00f6netimi eyl\u00fcl ay\u0131nda Sinopharm’\u0131n a\u015f\u0131 aday\u0131n\u0131n acil durum kullan\u0131m\u0131na onay verdi. \u015eirket, ge\u00e7en ay yapt\u0131\u011f\u0131 a\u00e7\u0131klamada, a\u015f\u0131 aday\u0131n\u0131n acil kullan\u0131m kapsam\u0131nda 1 milyon ki\u015fiye uyguland\u0131\u011f\u0131, “baz\u0131 ki\u015filerde g\u00f6r\u00fclen hafif semptomlar d\u0131\u015f\u0131nda” hastal\u0131k belirtisiyle kar\u015f\u0131la\u015f\u0131lmad\u0131\u011f\u0131n\u0131 bildirdi.<\/p>\n

K\u00f6rfez \u00fclkesi Birle\u015fik Arap Emirlikleri (BAE), 9 Aral\u0131k’ta a\u015f\u0131n\u0131n \u00fclkede y\u00fcr\u00fct\u00fclen \u00fc\u00e7\u00fcnc\u00fc a\u015fama klinik denemelerinde o ana dek 31 bin g\u00f6n\u00fcll\u00fc \u00fczerinde y\u00fczde 86 etkinlik sa\u011flad\u0131\u011f\u0131n\u0131 belirterek a\u015f\u0131n\u0131n yayg\u0131n kullan\u0131m\u0131na onay verdi\u011fini duyurdu.<\/p>\n

A\u015f\u0131 aday\u0131n\u0131n klinik denemelerine ev sahipli\u011fi yapan bir di\u011fer K\u00f6rfez \u00fclkesi Bahreyn, 13 Aral\u0131k’ta a\u015f\u0131n\u0131n yayg\u0131n kullan\u0131m\u0131na onay vererek BAE’yi izledi.<\/p>\n

Bir di\u011fer \u00c7inli ila\u00e7 \u015firketi Sinovac’\u0131n ayn\u0131 y\u00f6ntemle geli\u015ftirdi\u011fi “Coronavac” adl\u0131 a\u015f\u0131 aday\u0131 da form\u00fcl\u00fcnde vir\u00fcs\u00fcn etkisizle\u015ftirilmi\u015f bir versiyonunu i\u00e7eriyor.<\/p>\n

\u00c7in’de acil durum kullan\u0131m\u0131na onay verilen a\u015f\u0131 aday\u0131n\u0131n Brezilya’da s\u00fcrd\u00fcr\u00fclen 3’\u00fcnc\u00fc a\u015fama klinik denemeleri sonu\u00e7land\u0131. Sinovac’\u0131n Brezilya’daki klinik denemelerde i\u015f birli\u011fi yapt\u0131\u011f\u0131 Butantan Enstit\u00fcs\u00fc, 21 Aral\u0131k’ta yapt\u0131\u011f\u0131 a\u00e7\u0131klamada, \u015fu ana kadar al\u0131nan sonu\u00e7larda etkililik d\u00fczeyinin a\u015f\u0131lar i\u00e7in asgari s\u0131n\u0131r olan y\u00fczde 50’yi a\u015ft\u0131\u011f\u0131 bildirdi.<\/p>\n

Ayn\u0131 anda 5 farkl\u0131 a\u015f\u0131 i\u00e7in klinik denemelerin y\u00fcr\u00fct\u00fcld\u00fc\u011f\u00fc Brezilya’da en az yan etkiye yol a\u00e7an a\u015f\u0131 oldu\u011fu g\u00f6zlenen Coronavac, bu \u00fclkenin yan\u0131 s\u0131ra Endonezya ve T\u00fcrkiye’de de insanlar \u00fczerinde test ediliyor.<\/p>\n

Coronavac, 3’\u00fcnc\u00fc a\u015fama denemeler kapsam\u0131nda T\u00fcrkiye’de 17 Eyl\u00fcl’de insanlar \u00fczerinde test edilmeye ba\u015flanm\u0131\u015ft\u0131. Sa\u011fl\u0131k Bakan\u0131 Fahrettin Koca, 25 Kas\u0131m’da yapt\u0131\u011f\u0131 a\u00e7\u0131klamada, \u00c7in men\u015feli inaktif a\u015f\u0131 aday\u0131ndan k\u0131\u015f aylar\u0131nda toplam 50 milyon doz sat\u0131n almak \u00fczere s\u00f6zle\u015fme imzaland\u0131\u011f\u0131n\u0131 duyurmu\u015ftu.<\/p>\n

\u00c7inli \u015firketlerin b\u00fcy\u00fck \u00f6l\u00e7ekli \u00fcretim yapma kabiliyetlerinin a\u015f\u0131 tedarikinde \u00c7in men\u015feili \u00fcr\u00fcnlere avantaj sa\u011flayaca\u011f\u0131 \u00f6ng\u00f6r\u00fcl\u00fcyor. Hem Sinopharm hem de Sinovac, 2021’de tek ba\u015flar\u0131na birer milyar doz a\u015f\u0131 \u00fcretecek kapasiteye ula\u015fmay\u0131 hedefliyor.<\/p>\n

D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc (DS\u00d6) verilerine g\u00f6re 22 Aral\u0131k itibar\u0131yla d\u00fcnya genelinde 61 Kovid-19 a\u015f\u0131 aday\u0131, klinik denemelerle insanlar \u00fczerinde test edilirken, 172 a\u015f\u0131 aday\u0131 da klinik \u00f6ncesi geli\u015ftirme a\u015famas\u0131nda bulunuyor.<\/p>\n

\"\"<\/a><\/div>","protected":false},"excerpt":{"rendered":"

ANKARA (AA) – Kovid-19 a\u015f\u0131 adaylar\u0131ndan ikisi yayg\u0131n kullan\u0131m ve acil kullan\u0131m onaylar\u0131 al\u0131rken, Rusya’da ve \u00c7in’de geli\u015ftirilen baz\u0131 a\u015f\u0131 adaylar\u0131 s\u0131n\u0131rl\u0131 olarak kullan\u0131lmaya ba\u015fland\u0131. \u0130ngiltere’de ve ABD’de risk grubundaki ki\u015filere ilk a\u015f\u0131lar vuruldu. \u00c7ok say\u0131da \u00fclke a\u015f\u0131 tedariki i\u00e7in milyonlarca dozluk \u00f6n sat\u0131n al\u0131m s\u00f6zle\u015fmeleri imzalad\u0131. D\u00fcnyada en fazla umut ba\u011flanan potansiyel a\u015f\u0131lar aras\u0131nda \u00fc\u00e7 farkl\u0131 y\u00f6ntemle geli\u015ftirilen alt\u0131 aday \u00f6ne \u00e7\u0131k\u0131yor. Bunlar aras\u0131nda ABD ve \u0130ngiltere’de yayg\u0131n ve acil kullan\u0131m\u0131na onay verilen RNA temelli iki a\u015f\u0131, \u0130ngiltere ve Rusya’da geli\u015ftirilen vir\u00fcs vekt\u00f6r\u00fc i\u00e7eren iki a\u015f\u0131 ile \u00c7in’de geli\u015ftirilen iki inaktif a\u015f\u0131 bulunuyor. A\u015f\u0131 t\u00fcrleri A\u015f\u0131 \u00fcreticileri Kovid-19 a\u015f\u0131s\u0131n\u0131 […]<\/p>\n","protected":false},"author":1,"featured_media":7265,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[13],"tags":[991,1565,1834,2014,2390,708,1550,1837,2465,2466,460,2467],"class_list":["post-7264","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saglik","tag-asi","tag-astrazeneca","tag-biontech","tag-dna","tag-moderna","tag-oxford","tag-pandemi","tag-pfizer","tag-rna","tag-rus-asilari","tag-salgin","tag-sinopharm"],"_links":{"self":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts\/7264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/comments?post=7264"}],"version-history":[{"count":0,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts\/7264\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/media\/7265"}],"wp:attachment":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/media?parent=7264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/categories?post=7264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/tags?post=7264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}